Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. • Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. • The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. • Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.
Bibliographical noteFunding Information:
This position statement is developed by the Position Statement Writing Committee including Miseon Kim (committee secretary), Young-Han Kim (representative from the Korean Society of Maternal Fetal Medicine), Yong Beom Kim (affiliate of the scientific committee of the Korean Society of Obstetrics and Gynecology [KSOG]), Jayeon Kim (representative from the Korean Society for Reproductive Medicine), Jae-Weon Kim (committee chair), Mi Hye Park (affiliate of the scientific committee of KSOG), Joo Hyun Park (representative from the Korean Society of Gynecologic Endocrinology), Jeong Ho Rhee (affiliate of the scientific committee of KSOG), Myong Cheol Lim (representative from the Korean Society of Gynecologic Oncology [KSGO]) and Joon-Seok Hong (secretary of the scientific committee of KSOG). The position statement was reviewed and approved by all committee members. We would like to extend our gratitude to the KSGO advisors (Sunghoon Kim, Young-Tak Kim, Young Tae Kim, Jeong-Yeol Park, Dong Hoon Suh, Seung-Hyuk Shim, Keun Ho Lee, Jae-Kwan Lee, Sung Jong Lee, Soo Young Hur), advisors from the Korean Society for Laboratory Medicine (Seung-Man Park and Eun-Hee Nah), and the Korean Academy of Family Medicine advisor (Bumjo Oh) who provided insight and expertise that significantly assisted this position statement.
© 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.